The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression

Further Publications

The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy

Eur J Cancer

Plazy C, Boussena M, Nguyen Phuong L, Assié JB, Grolleau E, Gounant V, Decroisette C, Dansin E, Daniel C, Leprieur EG, Planchard D, Riudavets M, Canellas A, Oulkhouir Y, Pérol M, Toffart AC, Benzekry S, Gobbini E

doi: 10.1016/j.ejca.2025.116115

EHA/ICML 2025

Lymphoma

SAKK 38/19: PET/ctDNA-guided approach is feasible for treatment allocation in frontline DLBCL

ELCC 2025

Lung, Respiratory and Thoracic Cancer

EMPOWER-Lung 1: Continued cemiplimab beyond progression plus platinum-based chemotherapy is associated with favorable survival outcomes

Gastrointestinal Cancer

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

Int J Cancer

Potthoff K, Uhlig J, Jacobasch L, Müller L, Reiser M, de Buhr R, Polata S, Gerger A, Zehrer V, Amann A, Göhler T, Serrer L, Schröder J, Semsek D, Köhler A, Stübs P, Prager G, Siebenbach HU, Schuch A, Marschner N

doi: 10.1002/ijc.70139

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Gastrointestinal Cancer

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database

J Clin Oncol

Bachet JB, de Gramont A, Raeisi M, Rakez M, Goldberg RM, Tebbutt NC, Van Cutsem E, Haller DG, Hecht JR, Mayer RJ, Lichtman SM, Benson AB, Sobrero AF, Tabernero J, Adams R, Zalcberg JR, Grothey A, Yoshino T, André T, Shi Q, Chibaudel B

doi: 10.1200/JCO-24-01968

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

Breast Cancer

Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer

Ann Oncol

Mamann A, Pradat Y, Bidard FC, Delaloge S, Cabel L, Faull I, Marques S, Bachelot T, Dalenc F, DE LA Motte Rouge T, Pistilli B, Samaniego J, Frenel JS, Levy C, Ferrero JM, Sabatier R, Ladoire S, Chakiba C, Hardy AC, Lemonnier J, Mahi Y, Andre F, Cournede PH, Michiels S, Bernard E

doi: 10.1016/j.annonc.2025.06.015

Lung, Respiratory and Thoracic Cancer

Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non-Small Cell Lung Cancer With High Programmed Death-Ligand 1 Expression

JTO Clin Res Rep

Cheung AHK, Mui Z, Yeung WW, Chow C, Yu MF, Chen OH, Wong KY, Xie F, Lau YM, Cheng AS, Kang W, To KF, Mok TS, Li MSC

doi: 10.1016/j.jtocrr.2024.100754

Related content

The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy

SAKK 38/19: PET/ctDNA-guided approach is feasible for treatment allocation in frontline DLBCL

EMPOWER-Lung 1: Continued cemiplimab beyond progression plus platinum-based chemotherapy is associated with favorable survival outcomes

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database

Advancing Breast Cancer Treatment with Elacestrant

Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer

Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non-Small Cell Lung Cancer With High Programmed Death-Ligand 1 Expression